Use of anti-CD20 antibody in the treatment of post-transplant glomerulonephritis

Clinical Transplantation

Volumn 25, Issue 3, 2011, Pages 375-379

  Damodar, Amar ^a   Mustafa, Reem ^a   Bhatnagar, Jyotsna ^a   Panesar, Mandip ^a   Gundroo, Aijaz ^a   Zachariah, Mareena ^a   Blessios, George ^a   Tornatore, Kathleen ^a   Weber Shrikant, Edit ^a   Venuto, Rocco ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Glomerulonephritis; Plasmapheresis; Post transplant; Renal transplant; Rituximab

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CD20 ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS;

ADULT; ARTICLE; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; PLASMAPHERESIS; POSTTRANSPLANT GLOMERULONEPHRITIS; PRIORITY JOURNAL; PROTEINURIA;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLASMAPHERESIS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROTEINURIA; RISK FACTORS; SURVIVAL RATE;

EID: 79958703421     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01245.x     Document Type: Article

References (39)

1. Golgert WA, Appel GB, Hariharan S. Recurrent glomerulonephritis after renal transplantation: an unsolved problem. Clin J Am Soc Nephrol 2008: 3: 800.
2. 2007 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1997-2006. Rockville, MD: Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation.
3. Matas AJ, Gillingham KJ, Humar A et al. 2202 kidney transplant recipients with 10years of graft function: what happens next? Am J Transplant 2008: 8: 2410.
4. Chadban S. Glomerulonephritis recurrence in the renal graft. J Am Soc Nephrol 2001: 12: 394.
5. Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002: 347: 103.
6. Hariharan S, Peddi VR, Savin VJ et al. Recurrent and de novo renal diseases after renal transplantation: a report from the renal allograft disease registry. Am J Kidney Dis 1998: 31: 928.
7. Falk RJ, Jennette C, Nachman PH. Primary glomerular disease. In: Brenner BM, ed. Brenner and Rector's The Kidney, 7th edn, Vol. 1. Philadelphia: Saunders, 2004: 1293.
8. Laufer J, Ettenger RB, Ho WG, Cohen AH, Marik JL, Fine RN. Plasma exchange for recurrent nephrotic syndrome following renal transplantation. Transplantation 1988: 46: 540.
9. Cochat P, Kassir A, Colon S et al. Recurrent nephrotic syndrome after transplantation: early treatment with plasmaphaeresis and cyclophosphamide. Pediatr Nephrol 1993: 7: 50.
10. Dantal J, Baatard R, Hourmant M, Cantarovich D, Buzelin F, Soulillou JP. Recurrent nephrotic syndrome following renal transplantation in patients with focal glomerulosclerosis: a one-center study of plasma exchange effects. Transplantation 1991: 52: 827.
11. Häffner K, Zimmerhackl LB, Von Schnakenburg C, Brandis M, Pohl M. Complete remission of post-transplant FSGS recurrence by long-term plasmapheresis. Pediatr Nephrol 2005: 20: 994. Epub 2005 May 12.
12. Fencl F, Simková E, Vondrák K et al. Recurrence of nephrotic proteinuria in children with focal segmental glomerulosclerosis after renal transplantation treated with plasmapheresis and immunoadsorption: case reports. Transplant Proc 2007: 39: 3488.
13. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006: 6: 859.
14. Hristea D, Hadaya K, Marangon N et al. Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int 2007: 20: 102.
15. Nozu K, Iijima K, Fujisawa M et al. Rituximab treatment for post transplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 2005: 20: 1660. Epub 2005 Aug 16.
16. Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 2006: 354: 1961.
17. Yabu JM, Ho B, Scandling JD, Vincenti F. Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant 2008: 8: 222.
18. El-Firjani A, Hoar S, Karpinski J, Bell R, Deschenes MJ, Knoll GA. Post-transplant focal segmental glomerulosclerosis refractory to plasmapheresis and rituximab therapy. Nephrol Dial Transplant 2008: 23: 425. Epub 2007 Nov 2.
19. Meyer TN, Thaiss F, Stahl RA. Immunoadsorbtion and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis. Transpl Int 2007: 20: 1066. Epub 2007 Sep 20.
20. Marks SD, McGraw M. Does rituximab treat recurrent focal segmental glomerulosclerosis post-renal transplantation? Pediatr Nephrol 2007: 22: 158. Epub 2006 Aug 26.
21. Gossmann J, Scheuermann EH, Porubsky S, Kachel HG, Geiger H, Hauser IA. Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis. Transpl Int 2007: 20: 558. Epub 2007 Apr 13.
22. Meyer TN, Thaiss F, Stahl RA. Immediate versus long-term effect of rituximab in recurrent focal segmental glomerulosclerosis. Transpl Int 2008: 21: 1102.
23. Gallon L, Chhabra D. Anti-CD20 monoclonal antibody (rituximab) for the treatment of recurrent idiopathic membranous nephropathy in a renal transplant patient. Am J Transplant 2006: 6: 3017.
24. Cohen CD, Calvaresi N, Armelloni S et al. CD20-positive infiltrates in human membranous glomerulonephritis. J Nephrol 2005: 18: 328.
25. Sirimongkolrat T, Premasathian N, Vongwiwatana A, Limsrichamrern S, Cheunsuchon B, Vasuvattakul S. Anti-CD20 monoclonal antibody (rituximab) for the treatment of membranous nephropathy after living-unrelated kidney transplantation: a case report. Transplant Proc 2008: 40: 2440.
26. Quartuccio L, Soardo G, Romano G et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford) 2006: 45: 842. Epub 2006 Jan 17.
27. Nakayama M, Kamei K, Nozu K et al. Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol 2008: 23: 481.
28. Suri M, Tran K, Sharma AP, Filler G, Grimmer J. Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab. Int Urol Nephrol 2008: 40: 807.
29. Bartel C, Oberma Ller N, Rummel MJ, Geiger H, Hauser IA. Remission of a B cell CLL-associated memranoproliferative glomerulonephritis Type 1 with rituximab and bendamustine. Clin Nephrol 2008: 69: 285.
30. Segarra A, Praga M, Ramos N et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients [see comment]. Clin J Am Soc Nephrol 2009: 4: 1083.
31. Dello Strogolo I, Guzzo I, Laurenzi C et al. Use of rituximab in focal glomerulosclerosis relapses after renal transplantation. Transplantation 2009: 88: 417.
32. Tipping PG, Kitching AR. Glomerulonephritis, Th1 and Th2: what's new? Clin Exp Immunol 2005: 142: 207.
33. Nangaku M, Couser WG. Mechanisms of immune-deposit formation and the midiation of immune renal injury. Clin Exp Nephrol 2005: 9: 183.
34. Kurts C, Heymann F, Lukas-Kornek V, Boor P, Floege J. Role of T cells and dendritic cellis in glomerular immunopathology. Semin Immunopathol 2007: 29: 317. Epub 2007 Oct 23.
35. Kamar N, Faguer S, Esposito L et al. Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports. Clin Nephrol 2007: 67: 250.
36. Savin VJ, McCarthy ET, Sharma M. Permeability factors in focal segmental glomerulosclerosis. Semin Nephrol 2003: 23: 147.
37. Weclawiak H, Ribes D, Guilbeau-Frugier C et al. Relapse of membranous glomerulopathy after kidney transplantation: sustained remittance induced by rituximab. Clin Nephrol 2008: 69: 373.
38. Basse G, Ribes D, Kamar N et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 2005: 80: 1560.
39. Soler M, Mir M, Rodriguez E et al. Recurrence of IgA nephropathy and Henoch-Schönlein purpura after kidney transplantation: risk factors and graft survival. Transplant Proc 2005: 37: 3705.